{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"6.7","value":"3.08"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"10.5","value":"7.9"},{"groupId":"OG002","lowerLimit":"4.6","upperLimit":"16.1","value":"11.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"To evaluate the duration of response achieved with physician's choice selinexor-based combination therapy","dispersionType":"95% Confidence Interval","groups":[{"description":"Group 1:\n\n* Selinexor 60 mg PO days 1, 8, 15\n* Pomalidomide 4 mg PO on days 1-21\n* Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22\n* 28 day treatment cycles\n\nSelinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).\n\nPomalidomide: Oral Table\n\nDexamethasone: Oral tablet or injection","id":"OG000","title":"Group 1"},{"description":"Group 2:\n\nSelinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \\>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle Selinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).\n\nDaratumumab: Injection Dexamethasone: Oral tablet or injection","id":"OG001","title":"Group 2"},{"description":"Group 3:\n\n* Selinexor 80 mg PO days 1, 8, 15\n* Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15.\n* Dexamethasone 40 mg IV or PO days 1, 8, 15, 22\n* 28 day treatment cycle\n\nSelinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).\n\nCarfilzomib: Injection\n\nDexamethasone: Oral tablet or injection","id":"OG002","title":"Group 3"}],"paramType":"MEDIAN","populationDescription":"The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually. This analysis was preplanned in the study protocol. Analysis of the secondary endpoint of duration of response will be performed on the Intent-to-treat (ITT) population, which will include all subjects who have been enrolled for the study.","reportingStatus":"POSTED","timeFrame":"End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}